Results 51 to 60 of about 9,479 (179)

Stabilized Extracellular Vesicle Formulations for Inhalable Dry Powder Development

Small, Volume 22, Issue 16, 17 March 2026.
Extracellular vesicles (EVs) hold promise for chronic obstructive pulmonary disease (COPD) treatment but face challenges with storage and delivery. This study demonstrates the stabilization of lung fibroblast‐derived EVs using inulin, enabling freeze‐drying and spray‐drying.
Eva M. Jansen, Luke van der Koog, Robin A.B. Elferink, Karim Rafie, Anika Nagelkerke, Reinoud Gosens, Henderik W. Frijlink, Wouter L.J. Hinrichs   +7 more
wiley   +1 more source

Making the Old New Again Through the Process of Recombinant Innovation

Journal of Product Innovation Management, Volume 43, Issue 2, Page 290-312, March 2026.
ABSTRACT Academic Summary Recombinant innovation—the process through which atypical and unexpected combinations of knowledge generate novel outcomes—is a critical driver of organizational distinctiveness and market transformation. While prior research has focused on firm‐ and industry‐level mechanisms, less attention has been given to multilevel ...
Vittoria Magrelli, Josip Kotlar, Alfredo De Massis, Federico Frattini, Antonio Messeni Petruzzelli   +4 more
wiley   +1 more source

Repurposing Drugs as Bacteroides fragilis BFT‐3 Inhibitors in the Animal Infection Model Galleria mellonella

Annals of the New York Academy of Sciences, Volume 1557, Issue 1, March 2026.
This work establishes a newly developed Galleria mellonella infection model as a powerful, ethical platform for studying Bacteroides fragilis pathogenesis and therapy. Leveraging this model, the study identifies MOA4 as a potent BFT‐3 inhibitor that improves host survival, increases bacterial clearance, and synergizes with antibiotics without toxicity.
Ana Jiménez‐Alesanco, Marta Gómara‐Lomero, Hajar Jeblaoui, Sonia Vega, Adrián Velázquez‐Campoy, José Antonio Aínsa, Olga Abián   +6 more
wiley   +1 more source

The State Pharmacopoeia - main standard of quality of medicines and medical devices in the Republic of Kazakhstan

Регуляторные исследования и экспертиза лекарственных средств, 2018
Since the publication of the first edition of the Republic’s of Kazakhstan State Pharmacopoeia (RKSP) there have been significant changes in the requirements for the pharmacopoeia, and in the understanding of its role as the main standard of quality for ...
S. R. Musinov, A. U. Tulegenova
doaj  

Safety of 3′‐sialyllactose (3′‐SL) sodium salt produced with a derivative strain (Escherichia coli K‐12 MG1655 INB‐3SL_01) of E. coli K‐12 MG1655 (ATCC 700926) as a novel food pursuant to Regulation (EU) 2015/2283

EFSA Journal, Volume 24, Issue 3, March 2026.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3′‐sialyllactose (3′‐SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human‐identical milk oligosaccharide (HiMO) 3′‐SL (sodium salt),
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Margarita Aguilera‐Gómez, Thomas Frenzel, Harry J. McArdle, Peter Moldeus, Monika Neuhäuser‐Berthold, Josef Rudolf Schlatter, Henk van Loveren, Estefanía Noriega Fernández, Karen Ildico Hirsch‐Ernst   +23 more
wiley   +1 more source

Harmonization and updating as basic principles of the development of the Republic of Kazakhstan state pharmacopoeia

Регуляторные исследования и экспертиза лекарственных средств, 2018
The second edition of the Republic of Kazakhstan State Pharmacopoeia (RKSP 2.0) is the practical implementation of the principles of continuous development, harmonization and updating. Features of RKSP harmonization with the leading pharmacopoeias of the
S. R. Musinov, A. U. Tulegenova
doaj  

Safety and efficacy of a feed additive consisting of narasin and diclazuril (Interban®) for chickens for fattening and chickens reared for laying (Elanco GmbH)

EFSA Journal, Volume 24, Issue 3, March 2026.
Abstract Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the coccidiostat consisting of narasin and diclazuril (Interban®) for chickens for fattening and chickens reared for laying. The FEEDAP Panel concludes that the use of Streptomyces sp. NRRL B‐67771 in the production of
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Katerina Theodoridou, Maria Bastos, Georges Bories, Paul Brantom, Pier Sandro Cocconcelli, Jürgen Gropp, Mariana Petkova, Fernando Ramos, Guido Rychen, Luca Tosti, Ruud Woutersen, Jaume Galobart, Paola Manini, Alberto Navarro‐Villa, Elisa Pettenati, Fabiola Pizzo, Barbara Rossi, Maria Vittoria Vettori, Orsolya Holczknecht   +33 more
wiley   +1 more source

Approaches to Assessing the Quality of Fatty Oils and Medicinal Products Formulated as Oily Solutions

Регуляторные исследования и экспертиза лекарственных средств
INTRODUCTION. Vegetable fatty oils can comprise over 50% of a medicinal product formulated as an oily solution (in some cases, 100%). The quality of the vegetable fatty oil used and the processes occurring in this oil have a significant impact on the ...
A. A. Ponomarenko, L. I. Panova
doaj   +1 more source

Pharmaceutical Analytics at the Department of Pharmacy ETHZ

CHIMIA, 1997
Description of some research activities in Pharmaceutical Analysis, Irradiation of Pharmaceutical Drug Substances, Developement of Monographs on Pharmaceutical Substances for the European and Swiss Pharmacopoeia.
Hansruedi Altorfer
doaj   +2 more sources

Evaluation of Marketed Rosemary Essential Oils (Rosmarinus officinalis L.) in Terms of European Pharmacopoeia 10.0 Criteria. [PDF]

Turk J Pharm Sci, 2023
Barak TH, Bölükbaş E, Bardakcı H.
europepmc   +1 more source